PT1230932E - Uso de anticorpos para vacinacao contra o cancro - Google Patents

Uso de anticorpos para vacinacao contra o cancro

Info

Publication number
PT1230932E
PT1230932E PT02005394T PT02005394T PT1230932E PT 1230932 E PT1230932 E PT 1230932E PT 02005394 T PT02005394 T PT 02005394T PT 02005394 T PT02005394 T PT 02005394T PT 1230932 E PT1230932 E PT 1230932E
Authority
PT
Portugal
Prior art keywords
against cancer
antibodies
vaccination against
prophylactically
medicament
Prior art date
Application number
PT02005394T
Other languages
English (en)
Portuguese (pt)
Inventor
Hans Loibner
Helmut Eckert
Original Assignee
Igeneon Krebs Immuntherapie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Igeneon Krebs Immuntherapie filed Critical Igeneon Krebs Immuntherapie
Publication of PT1230932E publication Critical patent/PT1230932E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT02005394T 1999-01-13 2000-01-12 Uso de anticorpos para vacinacao contra o cancro PT1230932E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH5199 1999-01-13

Publications (1)

Publication Number Publication Date
PT1230932E true PT1230932E (pt) 2005-04-29

Family

ID=4178206

Family Applications (2)

Application Number Title Priority Date Filing Date
PT02005394T PT1230932E (pt) 1999-01-13 2000-01-12 Uso de anticorpos para vacinacao contra o cancro
PT00906191T PT1140168E (pt) 1999-01-13 2000-01-12 Vacinacoes contra o cancro

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT00906191T PT1140168E (pt) 1999-01-13 2000-01-12 Vacinacoes contra o cancro

Country Status (28)

Country Link
US (3) US7691372B2 (enExample)
EP (2) EP1230932B1 (enExample)
JP (1) JP4774551B2 (enExample)
KR (1) KR100771752B1 (enExample)
CN (1) CN1188169C (enExample)
AT (2) ATE286745T1 (enExample)
AU (1) AU768515B2 (enExample)
CA (1) CA2360382C (enExample)
CZ (1) CZ302801B6 (enExample)
DE (2) DE50000243D1 (enExample)
DK (2) DK1230932T3 (enExample)
EE (1) EE05474B1 (enExample)
ES (2) ES2177509T3 (enExample)
HK (1) HK1044487B (enExample)
HR (1) HRP20010526A2 (enExample)
HU (1) HU226150B1 (enExample)
ID (1) ID30223A (enExample)
IL (2) IL144265A0 (enExample)
IS (1) IS5998A (enExample)
MX (1) MXPA01007148A (enExample)
NO (1) NO329917B1 (enExample)
NZ (1) NZ512722A (enExample)
PL (1) PL201533B1 (enExample)
PT (2) PT1230932E (enExample)
SI (2) SI1230932T1 (enExample)
SK (1) SK286627B6 (enExample)
TR (1) TR200102034T2 (enExample)
WO (1) WO2000041722A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1230932B1 (de) * 1999-01-13 2005-01-12 Igeneon Krebs-Immuntherapie Forschungs- und Entwicklungs-AG Verwendung von Antikörpern zur Vakzinierung gegen Krebs
AT410172B (de) * 2000-03-21 2003-02-25 Igeneon Gmbh Verfahren zur herstellung einer vakzineformulierung
US20070122406A1 (en) 2005-07-08 2007-05-31 Xencor, Inc. Optimized proteins that target Ep-CAM
AT502293B1 (de) * 2002-05-15 2008-03-15 Igeneon Krebs Immuntherapie Immunogener, monoklonaler antikörper
AT500647A1 (de) * 2002-05-21 2006-02-15 Igeneon Krebs Immuntherapie Verwendung eines impfstoffes
AT500650B1 (de) 2003-04-17 2009-11-15 Altropus Gmbh Immunogener rekombinanter antikörper
AT500651B9 (de) * 2003-05-27 2010-04-15 Altropus Gmbh Aktiv immunisierender antikörper
WO2006005367A1 (en) 2004-07-14 2006-01-19 Igeneon Krebs-Immuntherapie Forschungs-Und Entwicklungs-Ag N-glycosylated antibody
EP1618890B1 (en) * 2004-07-20 2010-10-06 Altropus Gmbh Use of antibodies in a very low dose for the vaccination against cancer
CN101355928B (zh) * 2005-04-26 2013-05-22 卫材R&D管理株式会社 用于癌症免疫疗法的组合物和方法
EP1762575A1 (en) * 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
AT504231A1 (de) 2006-10-03 2008-04-15 Hans Dr Loibner Prädiktive parameter
EP2217253B1 (en) 2007-12-07 2011-06-29 N.V. Nutricia Bifidobacterium for dust mite allergy
MX2011007049A (es) 2009-02-24 2011-08-03 Esbatech Alcon Biomed Res Unit Metodos para identificar inmunoligadores de los antegenos de la superficie celular.
US8887373B2 (en) 2012-02-24 2014-11-18 Covidien Lp Vessel sealing instrument with reduced thermal spread and method of manufacture therefor
US20140276968A1 (en) * 2013-03-14 2014-09-18 Ethicon, Inc. Applicator systems for surgical fasteners
US10196458B2 (en) * 2013-07-26 2019-02-05 The Regents Of The University Of California Anti-immunoglobulin E antibodies and methods of using thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341281C (en) * 1986-07-09 2001-08-07 Hubert J.P. Schoemaker Immunotherapy of tumor with monoclonal antibody against the 17-1a antigen
US5270202A (en) 1989-11-03 1993-12-14 Syamal Raychaudhuri Anti-idiotypic antibodies to human melanoma-associated proteoglycan antigen
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5798100A (en) * 1994-07-06 1998-08-25 Immunomedics, Inc. Multi-stage cascade boosting vaccine
WO1997005597A1 (en) * 1995-07-31 1997-02-13 Litton Systems Canada Limited Flat panel pixel array incorporating photoconductive switches
EP0857176A1 (en) * 1995-10-25 1998-08-12 Centocor B.V. HUMAN EPITHELIAL ANTIGEN Ep-CAM DERIVED PEPTIDES AND THEIR USE
US6235280B1 (en) 1996-04-12 2001-05-22 Malaya Chatterjee Methods of delaying development of CEA-associated tumors using anti-idiotype antibody 3H1
IL121041A0 (en) * 1997-06-09 1997-11-20 Yeda Res & Dev Immunogenic compositions for induction of anti-tumor immunity
US6274143B1 (en) * 1997-06-13 2001-08-14 Malaya Chatterjee Methods of delaying development of HMFG-associated tumors using anti-idiotype antibody 11D10
ATE480566T1 (de) * 1998-06-15 2010-09-15 Quest Pharmatech Inc Immuntherapeutische zusammensetzung und verfahren zur behandlung von prostatakrebs
EP1230932B1 (de) * 1999-01-13 2005-01-12 Igeneon Krebs-Immuntherapie Forschungs- und Entwicklungs-AG Verwendung von Antikörpern zur Vakzinierung gegen Krebs
AU2001261371A1 (en) 2000-05-16 2001-11-26 New York University Anti-idiotypic antibody against fimh adhesin of uropathogenic type i-fimbriated escherichia coli, compositions containing same and method for using same

Also Published As

Publication number Publication date
ATE219687T1 (de) 2002-07-15
US20120003232A1 (en) 2012-01-05
IL144265A (en) 2006-08-20
AU768515B2 (en) 2003-12-18
KR20010101446A (ko) 2001-11-14
ES2177509T3 (es) 2002-12-16
SI1140168T1 (en) 2002-10-31
HRP20010526A2 (en) 2002-08-31
HK1044487A1 (en) 2002-10-25
PL201533B1 (pl) 2009-04-30
EP1140168A1 (de) 2001-10-10
CN1344167A (zh) 2002-04-10
WO2000041722A1 (de) 2000-07-20
CN1188169C (zh) 2005-02-09
TR200102034T2 (tr) 2001-11-21
US20070224202A1 (en) 2007-09-27
EP1230932B1 (de) 2005-01-12
PL364747A1 (en) 2004-12-13
CA2360382A1 (en) 2000-07-20
CA2360382C (en) 2011-05-24
EE05474B1 (et) 2011-10-17
DE50009240D1 (de) 2005-02-17
JP2002534481A (ja) 2002-10-15
SK9642001A3 (en) 2002-03-05
PT1140168E (pt) 2002-11-29
KR100771752B1 (ko) 2007-10-30
NO329917B1 (no) 2011-01-24
HU226150B1 (en) 2008-05-28
DK1230932T3 (da) 2005-04-25
US20100233178A1 (en) 2010-09-16
US8444974B2 (en) 2013-05-21
HUP0200527A2 (en) 2002-06-29
NZ512722A (en) 2003-07-25
DK1140168T3 (da) 2002-09-30
DE50000243D1 (de) 2002-08-01
NO20013093D0 (no) 2001-06-21
ATE286745T1 (de) 2005-01-15
AU2796400A (en) 2000-08-01
JP4774551B2 (ja) 2011-09-14
CZ302801B6 (cs) 2011-11-16
EP1140168B1 (de) 2002-06-26
ES2236375T3 (es) 2005-07-16
SI1230932T1 (en) 2005-06-30
US7691372B2 (en) 2010-04-06
EP1230932A3 (de) 2003-11-26
EE200100366A (et) 2002-10-15
CZ20012581A3 (cs) 2002-01-16
IL144265A0 (en) 2002-05-23
MXPA01007148A (es) 2002-03-27
SK286627B6 (sk) 2009-02-05
IS5998A (is) 2001-07-10
EP1230932A2 (de) 2002-08-14
ID30223A (id) 2001-11-15
HK1044487B (zh) 2005-09-16
NO20013093L (no) 2001-09-10

Similar Documents

Publication Publication Date Title
PT1230932E (pt) Uso de anticorpos para vacinacao contra o cancro
TR200001253T2 (tr) Tümöre özel antijenler
BRPI0412245A (pt) anticorpos de rg1 e usos destes
FR12C0004I2 (fr) Anticorps contre l'antigene ctla-4 humain et utilisation
DE60202877D1 (de) Gezieltes antikörper-verfahren
AR016821A1 (es) Procedimiento mejorado para la obtencion de precursores de insulina con puentes de cistina correctamente unidos
BR0108471A (pt) Objeto pré-formado para liberar um agente ativo a um paciente, e, processos de formação de um objeto pré-formado para liberar um agente e de liberação de um agente ativo a um paciente
CR8698A (es) Anticuerpos monoclonales al factor de crecimiento de hepatocito
BRPI0418317A (pt) vacina de aumento de crescimento à base de epitopo de neutralização
EA200401081A1 (ru) Fab-фрагменты моноклонального антитела человека, направленные против гликопротеина e2 hcv и обладающие нейтрализующей активностью in vitro
PT1024824E (pt) Composicao de vacina dispersivel solida para administracao oral
ATE511855T1 (de) Adjuvansformulierung zur scheimhaut-applikation
BR0213684A (pt) Uso de antagonistas do receptor de endotelina para o tratamento de doenças tumorìgenas
BR0010711A (pt) Uso de moléculas co-estimulatórias solúveis para intensificar respostas imunes
PT1229936E (pt) Uso de anticorpos anti-idiotipicos como vacina contra o cancro
BR0109164A (pt) Anticorpos monoclonais para o receptor humano para ldl, produção e uso dos mesmos
AR031641A1 (es) Combinacion inmunoterapeutica para el tratamiento de tumores que sobre-expresan receptores con actividad quinasa en residuos de tirosina
DE60125232D1 (de) Kleines säurelösliches sporenprotein und seine verwendungen
ATE490271T1 (de) Rezeptor, dessen verwendung sowie mausantikörper
BR0007814A (pt) Uso de anticorpos para a vacinação contra câncer
ATE483473T1 (de) Verwendung von antikörpern in einer sehr geringen dosis zur impfung gegen krebs
AR020765A1 (es) Anticuerpos monoclonales humanos contra el antigeno de tumor uk114 y celulas de linfocitos e hibridomas para su produccion
MY143402A (en) Preparations used in the treatment and prophilaxis of mycobacterial infections
AR041480A1 (es) Uso de un inhibidor de interleucina-2 (''il-2'')
CY1114835T1 (el) Πληρη ανθρωπινα αντισωματα εναντι ανθρωπινου 4-1ββ (cd137)